The FDA recently approved bevacizumab (Avastin, Genentech) for use in combination with intravenous 5-fluorouracil-based chemotherapy for the first-line treatment of metastatic CRC. Bevacizumab is the first angiogenesis inhibitor to be approved for use in the U.S. Genentech began to ship bevacizumab to wholesalers within 3 days of its approval.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.